Novo Nordisk Launches Ozempic in India: A Game Changer in Diabetes Management

Danish pharmaceutical company Novo Nordisk has released its type 2 diabetes treatment injection, Ozempic, in India. The drug, known globally for aiding weight loss, is available in a user-friendly pen device. Novo Nordisk aims to offer affordable healthcare solutions by making Ozempic accessible across India.

Novo Nordisk, a leading Danish pharmaceutical giant, unveiled its much-anticipated type 2 diabetes injection, Ozempic, in India on Friday. This treatment, renowned globally for its weight-loss advantages, is now available in a user-friendly 'FlexTouch Pen'.

In a move to make diabetes management both innovative and accessible, Novo Nordisk offers Ozempic at an introductory weekly cost of Rs 2,200. Vikrant Shrotriya, Managing Director of Novo Nordisk India, emphasized their commitment to competitive pricing while maintaining affordability aligned with countries similar to India.

The company is taking proactive measures to ensure widespread distribution across the nation. While Novo Nordisk takes charge of Ozempic's distribution, its partnership with Emcure Pharma focuses on other weight loss medications. Despite challenges, Novo Nordisk remains prepared for incoming competition as the patent for injectable semaglutide is set to expire next year.

(With inputs from agencies.)